Formulary
Lipegfilgrastim: Indications, Dosing, Side Effects and Interactions
For all granulocyte-colony stimulating factors Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils.
MedNext Academy | 3 min read
Lipegfilgrastim: Indications, Dosing, Side Effects and Interactions
For all granulocyte-colony stimulating factors Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils.
Drug action
For all granulocyte-colony stimulating factors Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils.
Indications and dose
**Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy**
- **Adult** (By Subcutaneous Injection): for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only) 6 mg, for each chemotherapy cycle, given approximately 24 hours after chemotherapy, dose expressed as filgrastim.
Cautions
For all granulocyte-colony stimulating factors Malignant myeloid conditions; pre-malignant myeloid conditions; risk of splenomegaly and rupture-spleen size should be monitored; sickle-cell disease Cautions, further information Acute respiratory distress syndrome There have been reports of pulmonary infiltrates leading to acute respiratory distress syndrome-patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk. Cautions For lipegfilgrastim Myelosuppressive chemotherapy
Side effects
For all granulocyte-colony stimulating factors Common or very common Arthralgia; cutaneous vasculitis; dyspnoea; haemoptysis; headache; hypersensitivity; leucocytosis; pain; spleen abnormalities; thrombocytopenia Uncommon Acute febrile neutrophilic dermatosis; capillary leak syndrome; hypoxia; interstitial pneumonia; pulmonary fibrosis; pulmonary oedema; respiratory disorders; sickle cell anaemia with crisis Side-effects, further information Treatment should be withdrawn in patients who develop signs of pulmonary infiltration. Side-effects For lipegfilgrastim Common or very common Chest pain; hypokalaemia; skin eruption
Interactions
**Other interactions (2):**
- Concomitant use of lipegfilgrastim with any chemotherapeutic medicinal product has not been evaluated in patients.
- The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated.
Pregnancy
For all granulocyte-colony stimulating factors Manufacturers advise avoid-toxicity in animal studies.
Breast feeding
For all granulocyte-colony stimulating factors There is no evidence for the use of granulocyte-colony stimulating factors during breast-feeding and manufacturers advise avoiding their use.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Lipegfilgrastim in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

